Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations

References

• Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011;17:107–15.
   PubMed Web of Science ®Google Scholar
• Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, Cooper C, . A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011;31(Suppl 2):30–60.
   Google Scholar
• Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730–9.
   PubMed Web of Science ®Google Scholar
• Strauss R, Torner A, Duberg AS, Hultcrantz R, Ekdahl K. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden—a low endemic country. J Viral Hepat 2008;15:531–7.
   PubMed Web of Science ®Google Scholar
• Gjertsen H, Weiland O, Oksanen A, Soderdahl G, Broome U, Ericzon BG. Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, Stockholm. Transplant Proc 2006;38:2675–6.
   PubMed Web of Science ®Google Scholar
• Duberg AS, Pettersson H, Aleman S, Blaxhult A, Daviethsdottir L, Hultcrantz R, . The burden of hepatitis C in Sweden: a national study of inpatient care. J Viral Hepat 2011;18:106–18.
   PubMed Web of Science ®Google Scholar
• Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, . Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010–7.
   PubMed Web of Science ®Google Scholar
• Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13:2467–78.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Cai T, Overbeck K, Bochud M, Dufour JF, Mullhaupt B, . Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655–66.
   PubMed Web of Science ®Google Scholar
• Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Lagging M. Association between IL28B-related genetic variants and liver histopathology differs between HCV genotypes. Hepatology 2012 Jan 23. [Epub ahead of print]
   Google Scholar
• Rembeck K, Alsio A, Christensen PB, Farkkila M, Langeland N, Buhl MR, . Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One 2012;7:e29370.
   PubMed Web of Science ®Google Scholar
• Bochud PY, Bibert S, Kutalik Z, Patin E, Guergnon J, Nalpas B, . IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 2012;55:384–94.
   PubMed Web of Science ®Google Scholar
• Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, . Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003;125:80–8.
   PubMed Web of Science ®Google Scholar
• Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, . Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001;345:1452–7.
   PubMed Web of Science ®Google Scholar
• Kamal SM, Moustafa KN, Chen J, Fehr J, Abdel Moneim A, Khalifa KE, . Duration of peginterferon therapy in acute hepatitis C: a randomized trial. Hepatology 2006;43:923–31.
   PubMed Web of Science ®Google Scholar
• Gane E, Stedman C, Hyland R, Sorensen R, Symonds W, Hindes R, . Once daily PSI-7977 plus ribavirin: pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV genotype 2 or 3. Hepatology 2011;54(Suppl):377.
   Google Scholar
• Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867–72.
   PubMed Web of Science ®Google Scholar
• Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, . A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–26.
   PubMed Web of Science ®Google Scholar
• Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009;30:557–76.
   PubMed Web of Science ®Google Scholar
• Wejdmark A, Weiland O. [Measurement of liver elasticity can differentiate high and low grade fibrosis. New method can reduce the need of liver biopsy in chronic hepatitis C]. Lakartidningen 2009;106:3420–3.
   Google Scholar
• Bochud PY, Bibert S, Negro F, Haagmans B, Soulier A, Ferrari C, . IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011;55:980–8.
   PubMed Web of Science ®Google Scholar
• Darling JM, Aerssens J, Fanning G, McHutchison JG, Goldstein DB, Thompson AJ, . Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology 2011;53:14–22.
   PubMed Web of Science ®Google Scholar
• Lagging M, Askarieh G, Negro F, Bibert S, Soderholm J, Westin J, . Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One 2011;6:e17232.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR) Incivo; 2011. Available at: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002313/human_med_001487.jsp&mid = WC0b01ac058001d124 (2011).
   Google Scholar
• European Medicines Agency. European Public Assessment Report (EPAR) Victrelis; 2011. Available at: www.ema.europa.eu/ema/index.jsp?curl = pages/medicines/human/medicines/002332/human_med_001464.jsp&mid = WC0b01ac058001d124 (2011).
   Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, . IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006;44:1617–25.
   PubMed Web of Science ®Google Scholar
• Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, . Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286–90.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000;95:2978–80.
   PubMed Web of Science ®Google Scholar
• Zarski JP, Bohn B, Bastie A, Pawlotsky JM, Baud M, Bost-Bezeaux F, . Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 1998; 28:27–33.
   PubMed Web of Science ®Google Scholar
• Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, . Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011;54:887–93.
   PubMed Web of Science ®Google Scholar
• Kamal SM, Fouly AE, Kamel RR, Hockenjos B, Al Tawil A, Khalifa KE, . Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology 2006;130:632–8.
   PubMed Web of Science ®Google Scholar
• Boesecke C, Vogel M. HIV and hepatitis C co-infection: acute HCV therapy. Curr Opin HIV AIDS 2011;6:459–64.
   Google Scholar
• Arends JE, van Assen S, Stek CJ, Wensing AM, Fransen JH, Schellens IM, . Pegylated interferon-alpha monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C. Antivir Ther 2011;16:979–88.
   Google Scholar
• Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–206.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, . Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2012;365:1014–24.
   Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–16.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G, . Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459–68 e1; quiz e14.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, . Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705–16.
   PubMed Web of Science ®Google Scholar
• Flamm S, Lawitz E, Jacobson IM, Rubin R, Bourliere M, Hezode C, . High sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus peginterferon alfa-2a/ribavirin. Poster 1366. EASL, Vienna, Austria, 2011.
   Google Scholar
• Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, . Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011;141:881–9 e1.
   PubMed Web of Science ®Google Scholar
• Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, . Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat 2008;15:641–5.
   PubMed Web of Science ®Google Scholar
• Manns M, Zeuzem S, Sood A, Lurie Y, Cornberg M, Klinker H, . Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol 2011;55:554–63.
   Google Scholar
• Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, . Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837–45.
   PubMed Web of Science ®Google Scholar
• Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, . Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/ml by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology 2008;48:695.
   PubMed Web of Science ®Google Scholar
• Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, . Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35–42.
   PubMed Web of Science ®Google Scholar
• von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, . Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522–7.
   PubMed Web of Science ®Google Scholar
• Yu ML, Dai CY, Huang JF, Hou NJ, Lee LP, Hsieh MY, . A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553–9.
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124–34.
   PubMed Web of Science ®Google Scholar
• Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannis SJ, . Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010;51:388–97.
   PubMed Web of Science ®Google Scholar
• Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, . HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311–21.
   PubMed Web of Science ®Google Scholar
• Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, . Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011;54:1250–62.
   PubMed Web of Science ®Google Scholar
• Vierling J, Flamm S, Gordon S, Lawitz E, Bronowicki J, Davis M, . Efficacy of boceprevir in prior null responders to peginterferon/ribavirin: the PROVIDE study. Hepatology 2011;54(4 Suppl):796–7.
   Google Scholar
• Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, . Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417–28.
   PubMed Web of Science ®Google Scholar
• Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, . Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206–12.
   PubMed Web of Science ®Google Scholar
• Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, . Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255–62.
   PubMed Web of Science ®Google Scholar
• Aleman S, Rahbin R, Davidsdottir L, Weiland O, Stål P, Carlsson T. Risk of hepatocellular carcinoma and liver complications in patients with HCV associated liver cirrhosis in a cohort of 490 patients: long-term effects of sustained virological response. Abstract OP423. 18^th United European Gastroenterology Week, Barcelona, Spain, 2010.
   Google Scholar
• Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, . Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652–7.
   PubMed Web of Science ®Google Scholar
• Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, . Sustained virologic response prevents the development of esophageal varices in compensated, Child–Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51:2069–76.
   PubMed Web of Science ®Google Scholar
• Hulskotte EG, Gupta S, Xuan F, van Zutven MG, O'Mara E, Galitz L, . Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and the calcineurin inhibitors cyclosporine and tacrolimus. Global Antiviral Journal 2011;7(Suppl 1; HEP Dart 2011):108–9.
   Google Scholar
• Lagging M, Wejstal R, Uhnoo I, Gerden B, Fischler B, Friman S, . Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations. Scand J Infect Dis 2009;41:389–402.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, . Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011;8:212–23.
   PubMed Web of Science ®Google Scholar
• Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit 2000;22:555–65.
   PubMed Web of Science ®Google Scholar
• Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004;11:84–7.
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Schvarcz R, Stahle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther Drug Monit 2002;24:701–8.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, . Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010;139:1602–11, e1.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, . A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008;15:370–8.
   PubMed Web of Science ®Google Scholar
• Thevenot T, Cadranel JF, Di Martino V, Pariente A, Causse X, Renou C, . A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C. Hepatology 2007;45:377–83.
   PubMedGoogle Scholar
• McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, . Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227–36.
   PubMed Web of Science ®Google Scholar
• Dominguez A, Bruguera M, Vidal J, Plans P, Salleras L. Community-based seroepidemiological survey of HCV infection in Catalonia, Spain. J Med Virol 2001;65:688–93.
   PubMed Web of Science ®Google Scholar
• Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998;27:108–17.
   PubMed Web of Science ®Google Scholar
• Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA, de Rueda PM, Quiles-Perez R, Gila-Medina A, . Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011;53:1830–8.
   PubMed Web of Science ®Google Scholar
• Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010;52:827–31.
   PubMed Web of Science ®Google Scholar
• Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, . The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450–8 e1.
   PubMed Web of Science ®Google Scholar
• Wirth S, Ribes-Koninckx C, Calzado MA, Bortolotti F, Zancan L, Jara P, . High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501–7.
   Web of Science ®Google Scholar
• Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, . Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005;41:1013–8.
   PubMed Web of Science ®Google Scholar
• Iorio R, Pensati P, Botta S, Moschella S, Impagliazzo N, Vajro P, . Side effects of alpha-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984–90.
   PubMed Web of Science ®Google Scholar
• Narkewicz MR, Cabrera R, Gonzalez-Peralta RP. The “C” of viral hepatitis in children. Semin Liver Dis 2007;27:295–311.
   PubMedGoogle Scholar
• Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, . Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054–8.
   PubMed Web of Science ®Google Scholar
• Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, . Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52:1035–40.
   PubMed Web of Science ®Google Scholar
• Dore GJ, Torriani FJ, Rodriguez-Torres M, Brau N, Sulkowski M, Lamoglia RS, . Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection. AIDS 2007;21:1555–9.
   PubMed Web of Science ®Google Scholar
• Falconer K, Askarieh G, Weis N, Hellstrand K, Alaeus A, Lagging M. IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV. Scand J Infect Dis 2010;42:896–901.
   PubMed Web of Science ®Google Scholar
• Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, . Effect of baseline CD4 cell count on the efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008;47:36–49.
   PubMedGoogle Scholar
• Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, . Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438–50.
   PubMed Web of Science ®Google Scholar
• Sherman KE, Rockstroh JK, Dieterich DT, Soriano V, Girard P, McCallister S, . Telaprevir combination with peginterferon alfa-2a/ribavirin in HCV/HIV coinfected patients: 24 week treatment interim analysis. Abstract LB-8. American Association for the Study of Liver Diseases (AASLD) Meeting, San Francisco, USA, 2011.
   Google Scholar
• Sulkowski M, Pol S, Cooper C, Fainboim H, Slim J, Rivero A, . Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients. Late breaker oral abstract LB-37. Infectious Diseases Society of America (IDSA) 49th Annual Meeting, Boston, MA, USA, 2011.
   Google Scholar
• Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, . Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972–82.
   PubMed Web of Science ®Google Scholar
• Bani-Sadr F, Goderel I, Penalba C, Billaud E, Doll J, Welker Y, . Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat 2007;14:639–44.
   PubMedGoogle Scholar
• Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, . Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon–ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007;45:123–5.
   PubMed Web of Science ®Google Scholar
• Margot NA, Miller MD. In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. Antivir Ther 2005;10:343–8.
   PubMedGoogle Scholar
• Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, . Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21–5.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Novoa S, Morello J, Gonzalez M, Vispo E, Barreiro P, Gonzalez-Pardo G, . Increase in serum bilirubin in HIV/hepatitis C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. AIDS 2008;22:2535–7.
   PubMed Web of Science ®Google Scholar
• Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, . Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680–7.
   PubMed Web of Science ®Google Scholar
• Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, . Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5:118–24.
   PubMed Web of Science ®Google Scholar
• Carrion JA, Navasa M, Garcia-Retortillo M, Garcia-Pagan JC, Crespo G, Bruguera M, . Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007;132:1746–56.
   PubMed Web of Science ®Google Scholar
• Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, . A randomized study on peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009–17.
   PubMed Web of Science ®Google Scholar
• EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. [Practice Guideline]. 2011;55:245–64.
   PubMed Web of Science ®Google Scholar